New Approaches with Precision Medicine in Adult Brain Tumors
暂无分享,去创建一个
[1] Liwu Fu,et al. KRAS mutation: from undruggable to druggable in cancer , 2021, Signal Transduction and Targeted Therapy.
[2] Jennie W. Taylor,et al. CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548 , 2021, Neuro-Oncology.
[3] J. Blay,et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial , 2021, The Lancet Oncology.
[4] W. Wick,et al. Emerging targets for anticancer vaccination: IDH , 2021, ESMO open.
[5] E. Maher,et al. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial , 2021, Clinical Cancer Research.
[6] P. Wen,et al. Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization. , 2021 .
[7] P. Brown,et al. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas. , 2021, The New England journal of medicine.
[8] S. Stevanović,et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma , 2021, Nature.
[9] S. Baker,et al. NTRK Fusions Can Co-Occur With H3K27M Mutations and May Define Druggable Subclones Within Diffuse Midline Gliomas. , 2021, Journal of neuropathology and experimental neurology.
[10] D. Reardon,et al. Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial , 2021, Cancer.
[11] A. Zhu,et al. Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation. , 2021 .
[12] Morgan Schmitt,et al. LGG-05. MOLECULAR GUIDED THERAPY FOR A PEDIATRIC LOW GRADE GLIOMA: A CASE REPORT , 2020, Neuro-Oncology.
[13] P. Wen,et al. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma , 2020, Clinical Cancer Research.
[14] S. Mueller,et al. Advances in Targeted Therapies for Pediatric Brain Tumors , 2020, Current Treatment Options in Neurology.
[15] M. Gil-Gil,et al. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO) , 2020, Targeted Oncology.
[16] Martha Donoghue,et al. FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors , 2020, Clinical Cancer Research.
[17] Mariella G. Filbin,et al. Molecular and clinicopathologic features of gliomas harboring NTRK fusions , 2020, Acta Neuropathologica Communications.
[18] Raymond Y Huang,et al. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Weller,et al. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.
[20] David T. W. Jones,et al. Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. , 2020, Cancer discovery.
[21] M. Ladanyi,et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.
[22] C. Antonescu,et al. Pan‐Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6–NTRK3 fusion , 2020, Histopathology.
[23] Hai Yan,et al. Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition. , 2020, Cancer research.
[24] L. Sekhar,et al. Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature , 2020, Case reports in pathology.
[25] I. Mellinghoff,et al. Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma , 2020, ACS medicinal chemistry letters.
[26] A. Walter,et al. Larotrectinib imaging response in low‐grade glioma , 2020, Pediatric blood & cancer.
[27] B. Taylor,et al. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations , 2019, Clinical Cancer Research.
[28] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[29] P. Fasching,et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. , 2019, The New England journal of medicine.
[30] E. Hwang,et al. Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors , 2019, Pediatric Drugs.
[31] M. J. van den Bent,et al. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma , 2019, Neuro-oncology.
[32] R. Verhaak,et al. Molecular Evolution of IDH Wild-Type Glioblastomas Treated With Standard of Care Affects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Drilon. TRK inhibitors in TRK fusion-positive cancers. , 2019 .
[34] A. Drilon,et al. TRK inhibitors in TRK fusion-positive cancers , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] P. Neven,et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.
[36] Arun K. Ramani,et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.
[37] E. Maher,et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. , 2019, The lancet. Gastroenterology & hepatology.
[38] S. Spiegl-Kreinecker,et al. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma , 2019, Acta Neuropathologica Communications.
[39] M. Ladanyi,et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls , 2019, Modern Pathology.
[40] L. Chow,et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. , 2019, The New England journal of medicine.
[41] F. Yamasaki,et al. Phase I study of a brain penetrant mutant IDH1 inhibitor DS-1001b in patients with recurrent or progressive IDH1 mutant gliomas. , 2019, Journal of Clinical Oncology.
[42] A. Drilon,et al. Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors. , 2019, Journal of Clinical Oncology.
[43] Jennie W. Taylor,et al. A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1. , 2019, Journal of Clinical Oncology.
[44] A. Drilon,et al. Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid Tumors , 2019, JCO precision oncology.
[45] Jessica L. Davis,et al. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] B. Tuch,et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. , 2019 .
[47] M. Khasraw,et al. Anti-epidermal growth factor receptor therapy for glioblastoma in adults. , 2019, The Cochrane database of systematic reviews.
[48] FDA approves larotrectinib for solid tumors with NTRK gene fusions , 2018, Case Medical Research.
[49] J. Sicklick,et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. , 2018, JCO precision oncology.
[50] A. Viale,et al. Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. , 2018, Cancer discovery.
[51] David M. Hyman,et al. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Hornick,et al. Expanding the spectrum of pediatric NTRK‐rearranged fibroblastic tumors to the central nervous system: A case report with RBPMS‐NTRK3 fusion , 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.
[53] M. Cowley,et al. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma , 2018, British Journal of Cancer.
[54] M. J. van den Bent,et al. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. , 2018, The Lancet Oncology.
[55] J. Swensen,et al. Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.
[56] Jennie W. Taylor,et al. Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma , 2018, Journal of Neuro-Oncology.
[57] J. Batanian,et al. Novel TLE4‐NTRK2 fusion in a ganglioglioma identified by array‐CGH and confirmed by NGS: Potential for a gene targeted therapy , 2018, Neuropathology : official journal of the Japanese Society of Neuropathology.
[58] D. Hong,et al. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins , 2018, Clinical Cancer Research.
[59] C. Fletcher,et al. Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.
[60] R. Collins,et al. Durable Remissions with Ivosidenib in IDH1‐Mutated Relapsed or Refractory AML , 2018, The New England journal of medicine.
[61] L. Trusolino,et al. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy , 2018, Nature Reviews Cancer.
[62] Fuhui Long,et al. An anatomic transcriptional atlas of human glioblastoma , 2018, Science.
[63] Rajeev Sharma,et al. Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature. , 2018, Pathology, research and practice.
[64] R. Bindra,et al. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib , 2018, Pediatric blood & cancer.
[65] Jessica L. Davis,et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.
[66] D. Schadendorf,et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. , 2018, The Lancet. Oncology.
[67] J. Huse,et al. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas , 2018, Journal of neuropathology and experimental neurology.
[68] J. Zenklusen,et al. SnapShot: TCGA-Analyzed Tumors , 2018, Cell.
[69] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[70] Martin Klein,et al. Lomustine and Bevacizumab in Progressive Glioblastoma , 2017, The New England journal of medicine.
[71] Brandon Nicolay,et al. EXTH-34. COMBINED USE OF THE PAN-IDH MUTANT INHIBITOR AG-881 WITH RADIATION THERAPY SHOWS ADDED BENEFIT IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO , 2017 .
[72] C. Brennan,et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence , 2017, Nature Genetics.
[73] M. Prados,et al. A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.
[74] Jason Y. Park,et al. Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas. , 2017, The Journal of the National Comprehensive Cancer Network.
[75] A. Drilon,et al. Somatic chromosomal engineering identifies BCAN-NTRK1 as a potent glioma driver and therapeutic target , 2017, Nature Communications.
[76] I. Flinn,et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. , 2017, Blood.
[77] R. Diaz,et al. The role of bevacizumab in the treatment of glioblastoma , 2017, Journal of Neuro-Oncology.
[78] A. Drilon,et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). , 2017, Cancer discovery.
[79] A. Iafrate,et al. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor , 2017, npj Precision Oncology.
[80] A. Unterberg,et al. Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo , 2017, Acta Neuropathologica.
[81] A. Hauschild,et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[82] M. Prados,et al. Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas , 2016, Oncotarget.
[83] H. Groen,et al. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[84] R. Finn,et al. Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.
[85] V. Rohde,et al. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms , 2016, Diagnostic Pathology.
[86] M. Weller,et al. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. , 2016 .
[87] J. Infante,et al. Targeting CDK4/6 in patients with cancer. , 2016, Cancer treatment reviews.
[88] S. Loi,et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet. Oncology.
[89] R. Bosotti,et al. Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications , 2016, Molecular Cancer Therapeutics.
[90] I. Mellinghoff,et al. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer , 2016, Clinical Cancer Research.
[91] Manish B. Patel,et al. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[92] J. Simes,et al. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. , 2015, Neuro-oncology.
[93] N. Lehman,et al. Primary Meningeal Pleomorphic Xanthoastrocytoma With Anaplastic Features: A Report of 2 Cases, One With BRAFV600E Mutation and Clinical Response to the BRAF Inhibitor Dabrafenib , 2015, Journal of neuropathology and experimental neurology.
[94] L. Créancier,et al. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. , 2015, Cancer letters.
[95] E. Lipp,et al. Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. , 2015, The oncologist.
[96] Katrina H. Smith,et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. , 2015, Neuro-oncology.
[97] M. Mehdorn,et al. A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. , 2015, European journal of cancer.
[98] A. Isacchi,et al. Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma , 2015, Acta neuropathologica communications.
[99] A. Gajjar,et al. Molecular characteristics of pediatric high-grade gliomas. , 2014, CNS oncology.
[100] P. Ascierto,et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.
[101] J. Utikal,et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.
[102] Nicolas Stransky,et al. The landscape of kinase fusions in cancer , 2014, Nature Communications.
[103] K. Aldape,et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[104] R. Vernhout,et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. , 2014, The Lancet. Oncology.
[105] B. Chauffert,et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. , 2014 .
[106] B. Chauffert,et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[107] S. Stevanović,et al. A vaccine targeting mutant IDH1 induces antitumour immunity , 2014, Nature.
[108] Chris Sander,et al. Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)) , 2014 .
[109] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[110] Jinkuk Kim,et al. NTRK1 Fusion in Glioblastoma Multiforme , 2014, PloS one.
[111] K. Hoang-Xuan,et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[112] Arie Perry,et al. BRAF-V600E mutation in pediatric and adult glioblastoma. , 2014, Neuro-oncology.
[113] John Y. K. Lee,et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas , 2014, Nature Genetics.
[114] N. Shah,et al. Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number data , 2013, BMC Genomics.
[115] T. Mikkelsen,et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] Raul Rabadan,et al. The integrated landscape of driver genomic alterations in glioblastoma , 2013, Nature Genetics.
[117] Jeanne Shen,et al. Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[118] Jesse S. Voss,et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. , 2013, Human pathology.
[119] Roland Eils,et al. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.
[120] M. Chamberlain. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series , 2013, Journal of Neuro-Oncology.
[121] D. Aisner,et al. Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation , 2013, The American journal of surgical pathology.
[122] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[123] S. Vaidhyanathan,et al. Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaFV600E Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[124] Tom Mikkelsen,et al. A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma , 2013, Clinical Cancer Research.
[125] A. Hauschild,et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[126] Daohai Yu,et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma , 2012, Journal of Neuro-Oncology.
[127] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.
[128] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[129] S. Söldner-Rembold,et al. The first 30 years , 1983 .
[130] H. Friedman,et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma , 2011, Journal of Neuro-Oncology.
[131] A. Grigoriadis,et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.
[132] B. Neyns,et al. Phase II study of sunitinib malate in patients with recurrent high-grade glioma , 2011, Journal of Neuro-Oncology.
[133] S. Pileri,et al. BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.
[134] C. James,et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. , 2011, International journal of radiation oncology, biology, physics.
[135] M. Ladanyi,et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] R. Klose,et al. The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.
[137] N. Rosen,et al. Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.
[138] Kirsten Schmieder,et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.
[139] Bin Wang,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.
[140] Manuela Zucknick,et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[141] Thomas Benner,et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[142] D. Birnbaum,et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms , 2010, Leukemia.
[143] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[144] Ken Chen,et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.
[145] A. Montpetit,et al. Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours , 2009, British Journal of Cancer.
[146] Christian Mawrin,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas , 2009, Acta Neuropathologica.
[147] Hendrik Witt,et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma , 2009, Acta Neuropathologica.
[148] Andrey Korshunov,et al. Analysis of the IDH1 codon 132 mutation in brain tumors , 2008, Acta Neuropathologica.
[149] David T. W. Jones,et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.
[150] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[151] D. Peeper,et al. BRAFE600 in benign and malignant human tumours , 2008, Oncogene.
[152] J. Pouysségur,et al. ERK implication in cell cycle regulation. , 2007, Biochimica et biophysica acta.
[153] G. Tzivion,et al. Raf kinases: function, regulation and role in human cancer. , 2007, Biochimica et biophysica acta.
[154] L. Reichardt,et al. Neurotrophin-regulated signalling pathways , 2006, Philosophical Transactions of the Royal Society B: Biological Sciences.
[155] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[156] D. Barford,et al. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.
[157] H. Namba,et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. , 2003, The Journal of clinical endocrinology and metabolism.
[158] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[159] F. Sommerer,et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma , 2003, Gut.
[160] M. Chao,et al. Neurotrophins and their receptors: A convergence point for many signalling pathways , 2003, Nature Reviews Neuroscience.
[161] P. Sorensen,et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.
[162] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[163] A. Nakagawara,et al. Trk receptor tyrosine kinases: a bridge between cancer and neural development. , 2001, Cancer letters.
[164] P. Sorensen,et al. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. , 1998, Cancer research.
[165] J. Fletcher,et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. , 1998, The American journal of pathology.
[166] P. Sorensen,et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.
[167] A. Bernheim,et al. Mapping of the Tyrosine Kinase Receptors trKA(NTRK1), trkB (NTRK2) and trkC(NTRK3) to Human Chromosomes 1q22, 9q22 and 15q25 by Fluorescence in situ Hybridization , 1997, European journal of human genetics : EJHG.
[168] M. Barbacid,et al. The trk proto-oncogene encodes a receptor for nerve growth factor , 1991, Cell.
[169] D. Kaplan,et al. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF , 1991, Nature.
[170] Hongen Liao,et al. A machine learning-based prediction model of H3K27M mutations in brainstem gliomas using conventional MRI and clinical features. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[171] S. Dahiya,et al. Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[172] L. Recht,et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.
[173] I. Flinn,et al. Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia , 2017 .
[174] Hai Yan,et al. Isocitrate dehydrogenase mutations in gliomas. , 2016, Neuro-oncology.
[175] R. Doebele,et al. TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.
[176] F. Ducray,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[177] R. Segal,et al. Growth, survival and migration: the Trk to cancer. , 2003, Cancer treatment and research.